Sickle-Cell Trait As A Risk Factor For Unprovoked Venous Thromboembolism: A Case Report, 2024 Drexel University
Sickle-Cell Trait As A Risk Factor For Unprovoked Venous Thromboembolism: A Case Report, James Cross, Brendan Mackey, Umme Yasmin
Tower Health Research Day
No abstract provided.
Lymphoma Revealed: Exploring Stroke-Like Patterns, 2024 Reading Hospital-Tower Health
Lymphoma Revealed: Exploring Stroke-Like Patterns, Mohammad Abu Tineh, Tan Tran, Mahmood Danishwar, Raesham Bukhari, Andrew Rettew
Tower Health Research Day
No abstract provided.
The Silent Culprit: Factor V Leiden’S Covert Role In Recurrent Miscarriages And First-Time Thromboembolism, 2024 Drexel University
The Silent Culprit: Factor V Leiden’S Covert Role In Recurrent Miscarriages And First-Time Thromboembolism, Tanner Aldous, Sarah Almarzooqi, Mingran Yu, Jeremy Ellis
Tower Health Research Day
No abstract provided.
When Potassium Cries Wolf: Pseudohyperkalemia In A Hospitalized Patient With Chronic Lymphocytic Leukemia, 2024 Drexel University College of Medicine
When Potassium Cries Wolf: Pseudohyperkalemia In A Hospitalized Patient With Chronic Lymphocytic Leukemia, Leyla Wade, Matthew Kent, Karen Avgush
Tower Health Research Day
No abstract provided.
A True Bloody Emergency: An Unusual Case Of Thrombotic Thrombocytopenic Purpura, 2024 The University of Texas Rio Grande Valley
A True Bloody Emergency: An Unusual Case Of Thrombotic Thrombocytopenic Purpura, Joshua M. Ninan
Research Symposium
Background: Thrombotic thrombocytopenic purpura (TTP) is a primary thrombotic microangiopathy that is classically characterized by thrombocytopenia and microangiopathic hemolytic anemia (MAHA). Although rare with an annual incidence of 3.7 cases per one million adults, it is considered a true hematological emergency due to its fatality rate of almost 100% if appropriate treatment is not initiated immediately. This makes it vitally important to identify and treat patients with TTP, a task that becomes unusually challenging in the absence of the disorder’s other characteristically diagnostic clinical features such as mucosal bleeding, fever, or presence of schistocytes.
Case Presentation: A 30-year-old gentleman with …
Myelodysplastic Syndrome With An Unusual De-Novo Gata1 Mutation In An Elderly Caucasian Male: A Case Report, 2024 HCA Healthcare
Myelodysplastic Syndrome With An Unusual De-Novo Gata1 Mutation In An Elderly Caucasian Male: A Case Report, Minh-Triet Nguyen, Maryam Fallahi, Talha Riaz
North Texas Research Forum 2024
Myelodysplastic syndrome (MDS) is a disorder of blood cell proliferation that has been shown to have multiple risk factors for pathogenesis. One risk factor well documented in existing literature is a mutation in GATA-binding factor 1 (GATA1) which is classically seen in younger individuals with Down syndrome. However, in our case report, we present an unusual presentation of MDS with a de novo GATA1 mutation in a 75-year-old male with no history of Down syndrome, who initially presented with isolaterombocytopenia. A 75-year-old male presented for evaluation of unexplained asymptomatic thrombocytopenia found incidentally on outpatient laboratory evaluation. Further evaluation of the …
Implementing A Standardized Screening Algorithm For Iron Deficiency Anemia In Pregnancy, 2024 HCA Healthcare
Implementing A Standardized Screening Algorithm For Iron Deficiency Anemia In Pregnancy, Ariel Moskowitz, Nicole Tenzel, Joshua Mangels, Lyndsay Millican
North Texas Research Forum 2024
OBJECTIVE: Anemia in pregnancy is a global health problem and complicates >40% of pregnancies. Anemia is associated with significant maternal and fetal complications including low birth weight, preterm delivery, postpartum hemorrhage, ICU admissions, need for blood transfusion, and maternal morbidity. The American College of Obstetricians and Gynecologists (ACOG) and the CDC recommend screening for anemia at the first prenatal visit and again between 24 and 28 weeks gestation. The aim of this quality improvement project is to improve compliance of screening for anemia in pregnancy amongst the providers of Medical City Women's Care. METHODS: Using the Plan-Do-Study-Act (PDSA) quality improvement …
Dermatologic Manifestations And Mixed Cryoglobulinemia In 40-Year Old Male, 2024 HCA Healthcare
Dermatologic Manifestations And Mixed Cryoglobulinemia In 40-Year Old Male, Sparsh Ray, Ben Tran, Bushra Ambreen
Gulf Coast Division Research Day 2024
No abstract provided.
Stigma And Patient-Controlled Analgesia: Trust Is The Essential Ingredient Of Successful Patient Education In The Patient-Doctor Relationship, 2023 Wayne State University
Stigma And Patient-Controlled Analgesia: Trust Is The Essential Ingredient Of Successful Patient Education In The Patient-Doctor Relationship, Trey D. Vanaken
Clinical Research in Practice: The Journal of Team Hippocrates
A clinical decision report using:
Van Beers EJ, Van Tuijn CFJ, Nieuwkerk PT, et al. Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. Am J Hematol. 2007;82(11):955-960. https://doi.org/10.1002/ajh.20944.
for a patient with recurrent vaso-occlusive crisis secondary to Sickle Cell Disease.
Hepatitis B Virus And B-Cell Lymphoma: Evidence, Unmet Need, Clinical Impact, And Opportunities, 2023 Thomas Jefferson University
Hepatitis B Virus And B-Cell Lymphoma: Evidence, Unmet Need, Clinical Impact, And Opportunities, Maya Rosenberg, Maria Poluch, Colin Thomas, Paola Sindaco, Alan Khoo, Pierluigi Porcu
Kimmel Cancer Center Faculty Papers
Nearly a billion people worldwide are infected with the hepatitis B Virus (HBV) and about a third of them have chronic infection. HBV is an important cause of morbidity and mortality, including acute and chronic hepatitis and hepatocellular carcinoma (HCC). Screening and control of primary HBV infection through vaccination represent a major advance in global public health, but large sections of the world population, in both developed and underdeveloped countries, remain unscreened and unvaccinated. In addition to being a global cause of liver disease, an important role of HBV in lymphoma has also emerged. First, the high risk of HBV …
Protein S Antibody As An Adjunct Therapy For Hemophilia B, 2023 LSU Health Sciences Center - New Orleans
Protein S Antibody As An Adjunct Therapy For Hemophilia B, Hope P. Wilson, Aliyah Pierre, Ashley L. Paysse, Narender Kumar, Brian C. Cooley, Pratyadipta Rudra, Adrianne W. Dorsey, Diana Polania-Villanueva, Sabyasachi Chatterjee, Maissaa Janbain, Maria C. Velez, Rinku Majumder
School of Medicine Faculty Publications
ABSTRACT: Hemophilia B (HB) is caused by an inherited deficiency of plasma coagulation factor IX (FIX). Approximately 60% of pediatric patients with HB possess a severe form of FIX deficiency (< 1% FIX activity). Treatment typically requires replacement therapy through the administration of FIX. However, exogenous FIX has a limited functional half-life, and the natural anticoagulant protein S (PS) inhibits activated FIX (FIXa). PS ultimately limits thrombin formation, which limits plasma coagulation. This regulation of FIXa activity by PS led us to test whether inhibiting PS would extend the functional half-life of FIX and thereby prolong FIX-based HB therapy. We assayed clotting times and thrombin generation to measure the efficacy of a PS antibody for increasing FIX activity in commercially obtained plasma and plasma from pediatric patients with HB. We included 11 pediatric patients who lacked additional comorbidities and coagulopathies. In vivo, we assessed thrombus formation in HB mice in the presence of the FIXa ± PS antibody. We found an accelerated rate of clotting in the presence of PS antibody. Similarly, the peak thrombin formed was significantly greater in the presence of the PS antibody, even in plasma from patients with severe HB. Furthermore, HB mice injected with PS antibody and FIX had a 4.5-fold higher accumulation of fibrin at the thrombus induction site compared with mice injected with FIX alone. Our findings imply that a PS antibody would be a valuable adjunct to increase the effectiveness of FIX replacement therapy in pediatric patients who have mild, moderate, and severe HB.
Investigating The Role Of Il-10 Producing Nkt Cells In Prevention Of Graft Versus Host Disease, 2023 The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences
Investigating The Role Of Il-10 Producing Nkt Cells In Prevention Of Graft Versus Host Disease, Drew Boagni
Dissertations & Theses (Open Access)
The standard curative treatment for hematologic malignancies is allogeneic stem cell transplantation (ASCT), in which the patient’s immune system is replaced with that of a healthy donor. This can lead to cure through the graft versus leukemia (GVL) effect but can also cause graft versus host disease (GVHD), which is characterized by systemic inflammation and organ damage mediated by dysregulated donor T cells. Preclinical studies have shown invariant natural killer T cells (iNKT) cells can prevent GVHD while preserving GVL. iNKT cells are unconventional T cells which recognize glycolipid antigens presented in the context of CD1d. Upon activation, they secrete …
Relative Reticulocytopenia, Erythropoietin, And Kidney Function In Patients With Sickle Cell Disease, 2023 St. Christopher's Hospital for Children
Relative Reticulocytopenia, Erythropoietin, And Kidney Function In Patients With Sickle Cell Disease, Richard Suarez, Nataly Apollonsky, Bruce Bernstein
St. Chris Research Day
No abstract provided.
A Rare Case Of Rapidly Progressive Cll/Sll Presenting As Bilateral Tonsillar Enlargement And Upper Airway Obstruction, 2023 HCA Healthcare
A Rare Case Of Rapidly Progressive Cll/Sll Presenting As Bilateral Tonsillar Enlargement And Upper Airway Obstruction, William Mangin, Kashif Aslam
North Texas Research Forum 2023
Although chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) differ in clinical presentation, they are both arise from the same pathologic process, namely the clonal expansion of mature B-cells. This malignancy is usually quite indolent and carries a favorable prognosis. Thanks to a number of highly-effective oral targeted therapies, such as the Bruton tyrosine kinase (BTK) inhibitor, Ibrutinib, patient outcomes have improved significantly. Unfortunately, these therapies are not always well tolerated and many patients are forced to discontinue the medication due to side effects. Many patients experience a disease flair and some even transformation to a high-grade malignancy after …
Covid-19 Masking An Atypical Presentation Of Hairy Cell Leukemia, 2023 HCA Healthcare
Covid-19 Masking An Atypical Presentation Of Hairy Cell Leukemia, Kahmalia-Kalee Sada
North Texas Research Forum 2023
Hairy cell leukemia is a rare lymphoid neoplasm of small mature B cell lymphoid cells. Hairy cell leukemia only accounts for about 1 to 2 percent of adult leukemia cases. Early diagnosis of Hairy cell Leukemia is important, it is proven that without treatment the median survival of this cancer is four years. After numerous studies the age-adjusted risk of death with proper diagnosis and treatment has decreased by 85%. The greatest outcomes are seen in individuals who are younger with earlier diagnosis. Hairy Cell Leukemia is a rare leukemia seen with the classic triad of splenomegaly, pancytopenia, and “hairy” …
Acute Thalamic Stroke In A Covid Positive Adult: A Case Report, 2023 HCA Healthcare
Acute Thalamic Stroke In A Covid Positive Adult: A Case Report, Norberto Escobales, Daniel Kiehl, Michelle Militello, Aleger Vorbes
South Atlantic Division Research Day 2023
No abstract provided.
A Case Of Type 1 Cryoglobulinemia With Waldenstrom’S Macroglobulinemia/Lymphoplasmocytic Lymphoma And Dry Gangrene, 2023 HCA Healthcare
A Case Of Type 1 Cryoglobulinemia With Waldenstrom’S Macroglobulinemia/Lymphoplasmocytic Lymphoma And Dry Gangrene, Abhinav Rao, Diego Garrido, Fahim Syed, Kody Dhaliwal, Charles Holladay, Julia Saylors, Matthew Madden, Jason Clark
South Atlantic Division Research Day 2023
No abstract provided.
Hemoglobinopathy Is Associated With Total Hip Arthroplasty Indication Even Beyond Sickle Cell Anemia, 2023 University of Kentucky
Hemoglobinopathy Is Associated With Total Hip Arthroplasty Indication Even Beyond Sickle Cell Anemia, Maxwell J. Rakutt, Daniel N. Bracey, Anna Cohen-Rosenblum, Peter K. Sculco, Franco M. Sabatini, Cale A. Jacobs, Stephen T. Duncan, David C. Landy
School of Medicine Faculty Publications
Background: The extent to which hemoglobinopathies other than sickle anemia (HbSS) are associated with hip osteonecrosis is unknown. Sickle cell trait (HbS), hemoglobin SC (HbSC), and sickle/β-thalassemia (HbSβTh) may also predispose to osteonecrosis of the femoral head (ONFH). We sought to compare the distributions of indications for a total hip arthroplasty (THA) in patients with and without specific hemoglobinopathies. Methods: PearlDiver, an administrative claims database, was used to identify 384,401 patients aged 18 years or older undergoing a THA not for fracture from 2010 to 2020, with patients grouped by diagnosis code (HbSS N = 210, HbSC N = 196, …
Does The Osteopathic Pedal Pump Reduce Lower Limb Volume In Healthy Subjects?, 2023 Rowan University
Does The Osteopathic Pedal Pump Reduce Lower Limb Volume In Healthy Subjects?, Jill S. Adams, Sahil H. Parikh, Brandon J. Goodwin, Donald R. Noll
Rowan-Virtua School of Osteopathic Medicine Faculty Scholarship
CONTEXT: Lymphatic treatments are gentle and passive techniques believed to enhance movement of lymph back into the central circulatory system. Animal studies provide supportive evidence, yet there are few studies in humans.
OBJECTIVES: The aim of this study is to investigate whether the osteopathic pedal pump protocol reduces volume in the lower limbs of healthy subjects.
METHODS: A total of 30 first- and second-year medical students were recruited. Subjects were excluded from participating if they had acute asthma, chronic obstructive pulmonary disease (COPD), congestive heart failure, active infections, fractures of the lower extremities, or metastatic cancer. A within-subjects study design …
Multiple Myeloma Diagnosed In A 23-Year-Old Male Presenting With Pathologic Compression Fracture, 2023 HCA Healthcare
Multiple Myeloma Diagnosed In A 23-Year-Old Male Presenting With Pathologic Compression Fracture, Kyle Combe, Tristan Myers, Michelle Levy, Greg Schlessinger
Continental, MidAmerica, & Mountain Divisions Research Day 2023
No abstract provided.